chufangao/CTO huggingface dataset:
Clinical trial NCT03490942: Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
Official title: Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Sponsor: Xeris Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Primary endpoint was not met
Enrollment: 49.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-03-15
Primary completion date: 2019-11-04
Completion date: 2020-02-10
Plan to share individual participant data: NO
Clinical trial NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
Official title: A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma
Sponsor: QBiotics Group Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Insufficient Patient Recruitment Rates
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-07
Primary completion date: 2022-07-12
Completion date: 2022-07-12
Clinical trial NCT03649321: Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Official title: A phase1b/2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funding was terminated early because research interests were going in a different direction.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-03
Primary completion date: 2022-06-27
Completion date: 2022-06-27
Baseline population: The study was terminated after the Phase 1b completed and prior to Phase 2 initiation.
Clinical trial NCT05065164: Denosumab and Screw Fixation for Osteoporotic Compression Fracture
Official title: Attending Doctor of Shenzhen People's Hospital
Sponsor: Shenzhen People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: no partcipants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-14
Primary completion date: 2023-03-20
Completion date: 2023-09-25
Plan to share individual participant data: NO
Clinical trial NCT03846258: High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy
Official title: High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy: a Pragmatic Randomized Control Trial
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Due to the fact that we were unable to find subjects who met all inclusion and exclusion criteria it was determined to withdraw this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2024-04-01
Completion date: 2024-04-01
Plan to share individual participant data: NO
Clinical trial NCT02603432: A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Official title: A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 700.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-25
Primary completion date: 2019-10-21
Completion date: 2023-03-28
Baseline population: The full analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03925727: Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Official title: Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye
Sponsor: Mimetogen Pharmaceuticals USA, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 623.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-28
Primary completion date: 2020-06-11
Completion date: 2020-06-11
Baseline population: Intent-to-treat (ITT) set included all randomized participants
Plan to share individual participant data: NO
Clinical trial NCT04336332: Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
Official title: Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Ineffectiveness of treatment
Enrollment: 75.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-01
Primary completion date: 2020-10-14
Completion date: 2020-10-14
Plan to share individual participant data: NO
Clinical trial NCT04565392: Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)
Official title: Proof-of-concept Randomized Placebo-controlled Trial of Famotidine for Outpatients With COVID-19
Acronym: Pepcid4COV19
Sponsor: drpykessupplements.com (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-01
Primary completion date: 2021-11-01
Completion date: 2022-01-31
Clinical trial NCT04175834: Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Official title: Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions
Acronym: PRECEPT
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-05
Primary completion date: 2022-05-13
Completion date: 2022-05-13
Clinical trial NCT02842125: Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Official title: Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
Sponsor: MultiVir, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Arm C rolled into parallel study; Arms A and B halted for greater efficacy in Arm C
Enrollment: 4.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-20
Primary completion date: 2020-05-08
Completion date: 2020-05-08
Plan to share individual participant data: NO
Clinical trial NCT02472938: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
Official title: Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis
Acronym: PROMPT
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2019-07-31
Completion date: 2020-07-31
Clinical trial NCT03802058: Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
Official title: Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer
Sponsor: Wuhan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was halted because enrollment was too slow
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-20
Primary completion date: 2021-12-12
Completion date: 2021-12-12
Plan to share individual participant data: YES
IPD sharing description: all IPD can be shared by all researchers who participate in this study by e-mail contact
IPD time frame: 2 years after the end of the study
IPD access criteria: Researchers who participate in this study
Clinical trial NCT04717362: The Effects of Natesto For Treatment Of Hypogonadism
Official title: The Effects of Natesto For Treatment Of Hypogonadism On Maintenance Of Spermatogensis.
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No longer wanting to enroll or start study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-03-01
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04770246: TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Official title: A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations
Sponsor: Taiho Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.
Enrollment: 17.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-31
Primary completion date: 2023-02-28
Completion date: 2023-03-06
Plan to share individual participant data: NO
Clinical trial NCT03745651: TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Official title: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 618.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-12-20
Primary completion date: 2019-11-18
Completion date: 2020-11-09
Baseline population: Intent-to-treat (ITT) population included all participants who were randomized to the study.
Plan to share individual participant data: NO
Clinical trial NCT04593641: This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
Official title: A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-04
Primary completion date: 2020-10-26
Completion date: 2021-04-05
Clinical trial NCT03377179: A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
Official title: A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Sponsor: RedHill Biopharma Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-07
Primary completion date: 2022-06-21
Completion date: 2022-06-21
Plan to share individual participant data: NO
Clinical trial NCT04355728: Use of UC-MSCs for COVID-19 Patients
Official title: Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-25
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Limitations and caveats: The inferences we make from the efficacy results observed in this phase 1/2a trial in 24 subjects, including the outcome of survival, are still subject to limitations of sample size and potential bias because of factors we were not yet aware of.
Plan to share individual participant data: NO
Clinical trial NCT05177770: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Official title: A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Coherus Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated for strategic reasons, not due to any safety concerns.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-17
Primary completion date: 2023-04-05
Completion date: 2023-04-05
Baseline population: The Safety Analysis Set included all participants who received any amount of study drug
Limitations and caveats: This study was originally intended to be conducted in 2 stages (1 and 2); however, a strategic decision was made to terminate the study during Stage 1.
Plan to share individual participant data: NO
Clinical trial NCT04962503: A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Official title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Due to Distal [M2 Segment and Beyond] Arterial Large Vessel Occlusion (LVO) or Perforator Occlusion and Who Are Ineligible for Intravenous Thrombolysis (IVT) or Endovascular Thrombectomy (EVT)
Sponsor: Clinuvel Pharmaceuticals Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-03
Primary completion date: 2022-02-04
Completion date: 2022-02-04
Clinical trial NCT05312021: Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
Official title: Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction: a Safety and Efficacy Phase 2 Randomized Clinical Study (SP9In-HFpEF)
Acronym: SP9In-HFpEF
Sponsor: Imara, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study Termination
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-30
Primary completion date: 2023-09-30
Completion date: 2023-11-30
Clinical trial NCT03425461: Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Official title: Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-14
Primary completion date: 2021-03-04
Completion date: 2021-03-04
Plan to share individual participant data: NO
Clinical trial NCT02245841: Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Official title: Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-06-15
Primary completion date: 2021-07-14
Completion date: 2021-07-14
Plan to share individual participant data: YES
IPD sharing description: Limited IPD will be shared within the publication.
IPD time frame: CDSAI-A scores and adverse events at each study assessment point will be included and available in the publication indefinitely.
IPD access criteria: Available to all.
Clinical trial NCT05600036: A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Sponsor: Alumis Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 228.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-09-27
Primary completion date: 2023-06-29
Completion date: 2023-07-25
Plan to share individual participant data: NO
Clinical trial NCT05179421: Dose Ranging Study of Intravenous Oxytocin for Analgesia to Heat Pain
Official title: A Dose Ranging Study for a Pharmacodynamic Model of Oxytocin for Peripheral Analgesia Effects
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-09
Primary completion date: 2023-02-10
Completion date: 2023-02-10
Baseline population: As noted in Participant Flow, there were 14 participants in Arm 1 and 11 participants in Arm 2. One subject in Arm 1 experienced near syncope during intravenous catheter insertion. This rapidly resolved spontaneously, but the subject did not further participate and did not receive study drug or undergo baseline testing.
Limitations and caveats: The original study design called for equal recruitment of subjects across three age ranges: young (18-39-year-old) middle (40 - 59-year-old) and older (60 - 75-year-old) with separate randomization in each group. The protocol was subsequently amended to remove this requirement.
Plan to share individual participant data: NO
Clinical trial NCT06006585: A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Official title: Safety, Tolerability, and Pharmacokinetics of Intravitreal Single Rising Doses and Multiple Doses of BI 771716 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized)
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-09-12
Primary completion date: 2024-05-24
Completion date: 2024-05-24
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to:~https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT03927222: Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Official title: I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Acronym: I-ATTAC
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Resource shortage
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-30
Primary completion date: 2023-02-10
Completion date: 2023-02-10
Plan to share individual participant data: NO
Clinical trial NCT04043806: A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Official title: A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 458.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-09
Primary completion date: 2022-12-14
Completion date: 2022-12-14
Baseline population: All participants who received at least one dose of the study drug were included in the baseline characteristics.
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing
Clinical trial NCT02975921: Betadine Pleurodesis Via Tunneled Pleural Catheters
Official title: Efficacy of Povidone-Iodine Instillation Via Tunneled Pleural Catheters in Achieving Pleurodesis: A Randomized Controlled Trial
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The site decided not to proceed with the protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-07-31
Primary completion date: 2020-09-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT04974970: Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
Official title: Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
Sponsor: University Hospital, Geneva (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: early termination due to insufficient recruitment
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-01
Primary completion date: 2022-04-19
Completion date: 2022-04-19
Clinical trial NCT04904185: ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Official title: Adoptive Transfer of ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) in Combination With Lymphodepletion and Anti-PD-1 to Patients With Metastatic Melanoma
Sponsor: Herlev Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of supply of scaffolds for T-cell expansion Evaluation of step A did not support addition of pembrolizumab in step B
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-17
Primary completion date: 2024-06-07
Completion date: 2024-07-02
Clinical trial NCT02384083: Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Official title: Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Sponsor: PETHEMA Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-09-30
Primary completion date: 2018-02-28
Completion date: 2020-03-23